Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction and Maintenance Therapy in Japanese Subjects With Moderate or Severe Ulcerative Colitis
Sponsor: Takeda
This PHASE3 trial investigates Ulcerative Colitis and is currently completed. Takeda leads this study, which shows 10 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
May 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Apr 2019 — May 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Apr 2019 [monthly]
Completed PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Aug 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Feb 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adachi-ku, Japan , Akashi-shi, Japan , Asahikawa-shi, Japan , Beppu-shi, Japan , Bunkyo-ku, Japan , Chikushino-shi, Japan , Chiyoda-ku, Japan , Edogawa City, Japan , Fujisawa-shi, Japan , Fukui-shi, Japan and 49 more locations